Ferguson BJ, Mitchell TG, Moon R, Camporesi EM, Farmer J, et al.
Reviews of infectious diseases. Date of publication 1988 May 1;volume 10(3):551-9.
1. Rev Infect Dis. 1988 May-Jun;10(3):551-9.
Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis.
Ferguson BJ(1), Mitchell TG, Moon R, Camporesi EM, Farmer J.
Author information:
(1)Department of Microbiology and Immunology, Duke University Medical Center,
Durham, North Carolina 27710.
The therapy of rhinocerebral mucormycosis includes aggressive surgical
debridement, administration of high-dose amphotericin B, and control of
underlying predisposing conditions, especially diabetes and immunosuppression or
immunodeficiency. Hyperbaric oxygen suppresses fungal growth in vitro and has
theoretical value in treating mucormycosis because it reduces the tissue hypoxia
and acidosis that accompany vascular invasion by the fungus. In a retrospective
review of patients at Duke University Medical Center with rhinocerebral
mucormycosis, six patients were treated with hyperbaric oxygen and seven cases
(involving six patients) were treated without hyperbaric oxygen. All patients
received surgical debridement and amphotericin B. Two of six patients receiving
hyperbaric oxygen therapy died, and four of seven patients not receiving
hyperbaric oxygen therapy died. Adverse effects from hyperbaric oxygen were
minimal. Because mucormycosis occurs infrequently, this retrospective review
involved a small number of patients. Despite this limitation, adjunctive
hyperbaric oxygen appears to be a promising clinical modality for the treatment
of rhinocerebral mucormycosis and warrants further investigation.
PMID: 3393782 [Indexed for MEDLINE]
